Trastuzumab-related subclinical cardiotoxicity in patients with early stage HER2-positive breast cancer: A retrospective single-center cohort study.

被引：0
|
作者：
Aseyev, Olexiy
Rushton-Marovac, Moira
Crawley, Freya L.
Johnson, Christopher
Dent, Susan Faye
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.10123
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
10123
引用
收藏
页数：5
相关论文
共 50 条
  • [1] Trastuzumab-Related Cardiotoxicity in Early Breast Cancer: A Cohort Study
    Bonifazi, Martina
    Franchi, Amatteo
    Rossi, Amarta
    Moja, Lorenzo
    Zambelli, Alberto
    Zambon, Antonella
    Corrao, Giovanni
    La Vecchia, Carlo
    Zocchetti, Carlo
    Negri, Eva
    ONCOLOGIST, 2013, 18 (07): : 795 - 801
  • [2] Left ventricular end-diastolic volume as an early indicator of Trastuzumab-related cardiotoxicity in patients with HER2 positive breast cancer: results from a single-center retrospective study
    Torelli, F.
    Bergamini, C.
    Ghiselli, L.
    Rossi, A.
    Trevisani, L.
    Vinco, G.
    Troung, S.
    Benfari, G.
    La Russa, F.
    Golia, G.
    Molino, A.
    Vassanelli, C.
    EUROPEAN HEART JOURNAL, 2016, 37 : 426 - 426
  • [3] Left ventricular end-diastolic volume as early indicator of trastuzumab-related cardiotoxicity in HER2+breast cancer patients: results from a single-center retrospective study
    Bergamini, Corinna
    Torelli, Flavia
    Ghiselli, Luca
    Rossi, Andrea
    Trevisani, Laura
    Vinco, Giulia
    Truong, Stella
    Benfari, Giovanni
    La Russa, Francesca
    Golia, Giorgio
    Molino, Annamaria
    Vassanelli, Corrado
    MINERVA CARDIOANGIOLOGICA, 2017, 65 (03): : 278 - 287
  • [4] Deceleration capacity of heart rate predicts trastuzumab-related cardiotoxicity in patients with HER2-positive breast cancer: A prospective observational study
    Feng, Yanying
    Qin, Zhenhua
    Yang, Zhijun
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2021, 46 (01) : 93 - 98
  • [5] Left atrial volume in patients with HER2-positive breast cancer: One step further to predict trastuzumab-related cardiotoxicity
    Bergamini, Corinna
    Dolci, Giulia
    Rossi, Andrea
    Torelli, Flavia
    Ghiselli, Luca
    Trevisani, Laura
    Vinco, Giulia
    Truong, Stella
    La Russa, Francesca
    Golia, Giorgio
    Molino, Annamaria
    Benfari, Giovanni
    Ribichini, Flavio Luciano
    CLINICAL CARDIOLOGY, 2018, 41 (03) : 349 - 353
  • [6] Trastuzumab-Related Cardiotoxicity and Cardiac Care in Patients With HER2 Positive Metastatic Breast Cancer
    Calvillo-Arguelles, Oscar
    Abdel-Qadir, Husam
    Suntheralingam, Sivisan
    Michalowska, Maria
    Amir, Eitan
    Thavendiranathan, Paaladinesh
    AMERICAN JOURNAL OF CARDIOLOGY, 2020, 125 (08): : 1270 - 1275
  • [7] Cardiac safety of trastuzumab without an anthracycline in patients with HER2-positive early stage breast cancer: A single center experience
    Mukku, R. B.
    Verma, S.
    Liu, J.
    Steingart, R.
    Hudis, C.
    Yu, A. F.
    Dang, C.
    CANCER RESEARCH, 2016, 76
  • [8] Cardiac safety of trastuzumab without an anthracycline in patients with HER2-positive early stage breast cancer: A single center experience
    Mukku, R. B.
    Verma, S.
    Liu, J.
    Steingart, R.
    Hudis, C.
    Yu, A. F.
    Dang, C.
    CANCER RESEARCH, 2016, 76
  • [9] Incidence of cardiotoxicity of trastuzumab in Her2Neu positive breast cancer patients: a retrospective cohort study
    Liesting, C.
    Brugts, J. J.
    Levin, M. -D.
    Kofflard, M. J. M.
    EUROPEAN HEART JOURNAL, 2011, 32 : 292 - 293
  • [10] Observational study of trastuzumab-related cardiotoxicity in early and metastatic breast cancer
    Grazziotin, L. R.
    Picon, P. D.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2017, 23 (04) : 264 - 272
12345